Arkayli Biopharma
Our mission is to develop novel medications with precision drug delivery systems to enhance efficacy and maximize safety of treatments for children and adults with vascular anomalies. Our lead product candidate, ARK001, has the potential to be the first FDA-approved non-systemic topical (applied to the skin) treatment for infantile hemangioma (IH).
ARK001 has the potential to change the approach to care for IH, allowing pediatricians and dermatologists to treat before the IH requires systemic therapy.
Our novel technology is designed to deliver a topical treatment for IH with benefits for infants, their families, and their caregivers.
ARK001 is an investigational treatment designed for the following characteristics:
A safe, effective treatment that can be applied directly to the IH on the skin.
A treatment that works locally – minimal systemic exposure.
A formulation that delivers 24-hour treatment to the IH, from just a single daily application on the skin.
A product that is convenient, and washes off easily with mild soap and water after 24 hours.